Presentations of the ESMO Magnitude of Clinical Benefit Scale
Since its publication in Annals fo Oncology, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been presented on a number of occassions
ESMO 2016 Congress: October 2016
The scale was presented or referenced during the following sessions at the ESMO 2016 congress:
Saturday, 8 October: Poster Display; 13:00-14:00, Hall E
Abstract 1511P: TKIs in first-line for advanced NSCLC with activating EGFR-mutations: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized controlled trials
Saturday, 8 October: Poster Discussion session; 16:30-17:30, room Helsinki
Abstract:1365PD Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?
Sunday, 9 October: Special Session; 14:45-16:15, room Helsinki
Clinical benefit of Cancer Drugs
Monday, 10 October: Special Symposium; 11:00-12:30, room Helsinki
ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing in the magnitude of clinical benefit
Monday, 10 October: Proffered Paper session; 16:30-18:00, room Oslo
Abstract 1364O: The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna
During an ESMO Asia 2015 Special Session, Resource constraints as a barrier to lung cancer management: Developing nations, C. Zielinski presented the ESMO Magnitude of Clinical Benefit Scale.
The scale was presented at the ESMO Society Session (28 September) during the European Cancer Congress 2015 in Vienna, Austria. E.G. de Vries, Netherlands, presented the scale and A. Eniu, Romania explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.
In addition, aspects of the ESMO-MCBS were highlighted and discussed during three further sessions at ECC 2015:
- ESO Society Session: ‘Is innovation Affordable?’, 26 September: The ESMO initiative on affordable drugs, Speaker: M. Piccart (Belgium)
- Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September: The Value of anticancer treatment, Speaker: E. G. de Vries (Netherlands)
- Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September: Chair: E.G. de Vries (Netherlands); Clinical Benefit scale: The European proposal, Speaker: M. Piccart (Belgium); Clinical Benefit scale: The challenge of fairness, Speaker: U. Dafni (Greece)
ESMO-MCBS presented at the ESMO/ASCO Joint Session (30 May) during ASCO 2015, Chicago
World Cancer Congress 2016, Paris, France (31 October – 3 November 2016). The ESMO Magnitude of clinical benefit scale and the value of cancer care, E. G. de Vries (Netherlands)